Skip to main content
SpringerLink
Log in
Book cover

Antibiosis and Host Immunity pp 279–290Cite as

Prohost Modulation of Immunity by Isoprinosine and NPT 15392

  • Chapter

Abstract

Antimicrobial agents which act on nucleic acids (e.g., rifampin, sulfonamides, trimethoprim, metronidazole), on ribosomes (e.g., tetracyclines, chloramphenicol, aminoglycosides) or on cytoplasmic membranes (e.g., amphotericin B, griseofulvin, polymyxin, imidazoles) positively influence the outcome of infections by acting against the offending pathogens but they may also have negative effects on the host’s immunocompetence (22). Although the immunosuppressive properties of most of the antimicrobials are not sufficient to warrant restricting their use, under certain circumstances a “pro-host” immunopharmacological approach seems warranted. In this regard it is important to remember that the immune system “cures” an infection, not the antimicrobial agent, and under circumstances where antimicrobial therapy is lifesaving, the host’s immune defenses are almost invariably compromised. To expedite the development of immunorestorative therapy it is important first of all to characterize the immunological deficiency which precedes, accompanies or follows a disease in order to select the appropriate immunorestorative agent. Secondly, new therapeutic strategies, where the antimicrobials are associated with prohost immunomodulating drugs, need to be studied in the appropriate animal systems.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. A. Azzara, A. Meozzi, G. Carulli, M. Martelli, F. Tangheroni, E. Serravalle and F. Ambrogi, Normalizzazione di funzioni neutrofiliche in bambini affetti da infezioni croniche ricorrenti dopo terapia ciclica con metisoprinolo, Chemioterapia 3:179 (1983).

    Google Scholar 

  2. C. Balestrino, E. Montesoro, A. Nocera, M. Ferrarini and T. Hoffman, Incremento dell’ attivita NK di cellule mononucleate di sangue periferico umano dopo trattamento con metisoprinolo, Biol. Resp. Modifiers 2:577 (1983).

    CAS  Google Scholar 

  3. M. Bechi and A. Cini, L’impiego del metisoprinolo nel trattamento della epatite virale acuta, Clin. Europea. 20:79 (1981).

    Google Scholar 

  4. R. F. Betts, R. G. Douglas, S. D. George and C. J. Rinehart, Isoprinosine in experimental influenza A infection in volunteers, 78th Annual Meeting of A.S.M., Las Vegas, Nevada (1978).

    Google Scholar 

  5. L. J. Bradshaw, H. L. Sumner, W. H. Wickett, Jr. and E. B. Correia, Immunological and clinical studies on herpes simplex patients treated with inosiplex, 4th International Congress of Immunology, Paris, Abst. 17.7.5 (1980).

    Google Scholar 

  6. S. Catania, F. Zennaro, P. Vittucci and M. Monacelli, Indagine clinica sul trattamento della varicella con isoprinosina, G. Mal. Inf. 35:194 (1983).

    Google Scholar 

  7. I. Cerutti, C. Chany and J. F. Schlumberger, Isoprinosine increases the antitumor action of interferon, Int. J. Immunopharmacol. 1:59 (1979).

    Article  PubMed  CAS  Google Scholar 

  8. T. W. Chang and L. Weinstein, Antiviral activity of isoprinosine in vitro and in vivo, Am. J. Med. Sci. 265:143 (1973).

    Article  PubMed  CAS  Google Scholar 

  9. P. Cornaglia-Ferraris, R. Coffey and J. W. Hadden, Purine substituted analogs as immunomodulators, EOS 4:134 (1984).

    Google Scholar 

  10. M. Danto, R. Colella, G. Borrelli, G. LaBella and R. Mele, L’uso di metisoprinolo in corso di broncopeumopatie croniche riacutizzate, Clin. Europea. 20:130 (1981).

    Google Scholar 

  11. M. D’Aquino, A. Borri, E. Radin, S. Scremin and L. Caprioglio, Efficacia del metisoprinolo nella terapia delle epatiti acute virali, 11th Congr. Naz. A.M.O.I., G. Mal. Infett. 34:1746 (1982).

    Google Scholar 

  12. S. W. D’Arca, A. Pana and M. Grassi, Attivita del metisoprinolo nei confronti del virus rabbico: Valutazione in vitro, EOS 3:8 (1983).

    Google Scholar 

  13. G. Delogu, D. Meli, C. DeSimone, G. Cristina, A. Lozzi and G. DeRitis, Impiego del metisoprinolo in un caso di poliradicolonevrite virale a prevalente incidenza bulbare, XI Congresso Nazionale A.M.O.I., Napoli giugno (1981).

    Google Scholar 

  14. C. DeSimone, G. W. Canonica, G. Corte and D. Meli, Influence of methisoprinol on surface antigens of T lymphocytes, Curr. Chemother. Immunother. 1:1161 (1982).

    Google Scholar 

  15. C. DeSimone, C. Capozzi, S. Campo, D. Ricca and G. Matteucci, Effetto dell’ azatioprina e dell’ inosiplex sulla formazione di rosette da parte dei linfociti di soggetti sani e di pazienti con neoplasie, Ann. Sclavo. 23:116 (1981).

    CAS  Google Scholar 

  16. C. DeSimone, A. Cilli, S. Zanzoglu and F. Matricardi, Results of clinical trials with methisoprinol in Italy, EOS 4:108 (1984).

    Google Scholar 

  17. C. DeSimone, G. Delogu, L. Pugnaloni and C. Mastropietro, Methisoprinol and corticosteroids: Immunopharmacokinetic assessment, Tissue Reactions 1:101 (1984).

    Google Scholar 

  18. C. DeSimone, A. Koverech, L. Pugnaloni, C. Mastropietro, M. C. Salis and F. Sorice, Defective adenosine-inducible suppressor T lympho-cyte generation by NPT 15392 and methisoprinol, Int. J. Immunother. 1:67 (1985).

    CAS  Google Scholar 

  19. C. DeSimone, D. Meli, M. Sbricoli, E. Rebuzzi and A. Koverech, In vitro effect of inosiplex on T lymphocytes: Influence on T cells with receptors for IgG (Ty), Int. J. Immunopharmacol. 4:139 (1982).

    CAS  Google Scholar 

  20. C. DeSimone, L. Pugnaloni, S. DeSantis, L. Baldinelli and F. Sorice, Influence of methisoprinol on kinetics of immune interferon production and blastogenesis, Int. J. Immunopharmacol. 3:317 (1985).

    Article  Google Scholar 

  21. C. DeSimone, A. Ricca, A. Lozzi and L. Lucci, Influence of methisoprinol on 0KT4+, 0KT8+, 0KM1+, 0KIal+ cells, Int. J. Immuno-pharmacol. 4:291 (1982).

    Article  Google Scholar 

  22. R. Finch, Immunomodulating effects of antimicrobial agents, J.Antimicrobiol. Chemother. 6:691 (1980).

    Article  CAS  Google Scholar 

  23. I. Florentin, M. Bruley-Rosset, J. Schulz, M. Davigny, N. Kiger and G.Mathe, Attempt at functional classification of chemically-defined immunomodulators, in: “Advances in Immunopharmacology,” J. W. Hadden, L. Chedid, P. Mullen and F. Spreafico, eds., Pergamon Press, Oxford (1981).

    Google Scholar 

  24. I. Florentin, E. Taylor, M. Davigny, C. Mathe and J. W. Hadden, Kinetic studies of the immunopharmacologic effects of NPT 15392 in mice, Int. J. Immunopharmacol. 4:225 (1982).

    Article  PubMed  CAS  Google Scholar 

  25. V. Frappamaina, L. Monno, F. Trotta and G. Pastore, Clearance sierica dell ’HB e AG nell ’epatite acuta di tipo B trattata con metiso-prinolo, EOS 2:115 (1982).

    Google Scholar 

  26. H. Friedman, R. Calle and A. Morin, Double-blind study of isoprinosine influence on immune parameters in solid tumor-bearing patients treated by radiotherapy, Int. J. Immunopharmacol. 2:194 (1980).

    Article  Google Scholar 

  27. M. Galli, A. Lazzarin, M. Moroni and C. Zanussi, Inosiplex in recurrent herpes simplex infections, Lancet 2:331 (1982).

    Article  PubMed  CAS  Google Scholar 

  28. T. Ginsberg, Urinary excretion of purine metabolites in macaca mulatta following administration of inosine and l-(dimethylamino)-2-pro-panol, p acetamidobenzoate, 5th Congress Pharmacology, S. Francisco, CA (1972).

    Google Scholar 

  29. T. Ginsberg and A. J. Glasky, Inosiplex: an immunomodulation model for the treatment of viral disease, Third conference on antiviral substances, Ann. N. Y. Acad. Sci. 284:128 (1977).

    Article  PubMed  CAS  Google Scholar 

  30. A. J. Glasky, G. E. Friebertshauser, J. W. Halker, R. A. Settineri and T. Ginsberg, The role of cell mediated immunity in the therapeutic action of viral disease processes, Chemotherapy 6:235 (1976).

    Google Scholar 

  31. A. Glasky, J. Gordon, F. Hoehler, J. Wallace and J. C. Bekesi, Isoprinosine (INPX) in progressive generalized lymphodenopathy (PGC) -kinetics of action and clinical response, Int. J. Immunopharmacol. 7:318 (1985).

    Article  Google Scholar 

  32. P. Gordon and E. R. Brown, The antiviral activity of isoprinosine,Can. J. Microbiol. 18:1463 (1972).

    Article  PubMed  CAS  Google Scholar 

  33. P. Gordon, B. Ronsen and E. R. Brown, Anti-herpes virus action of isoprinosine, Antimicrob. Agents Chemother. 5:153 (1974).

    PubMed  CAS  Google Scholar 

  34. P. Gordon and B. Rosen, Isoprinosine: biochemical correlates of antiviral and experimental learning-enhancing activities, FASEB 29:684 (1970).

    Google Scholar 

  35. A. Goutner, In vitro modulation of natural killer cell activity by isoprinosine, NPT 15392, and interferon, Int. J. Immunopharmacol. 2:197 (1980).

    Article  Google Scholar 

  36. G. Grippaudo, V. Diminiello and G. Fratto, Il metisoprinolo nel trattamento delle manifestazioni erpetiche intra ed extra-orali, Inform. Sanitario 4:1 (1982).

    Google Scholar 

  37. J. W. Hadden, P. Cornaglia-Ferraris and R. Coffey, Purine analogs as immunomodulators, in: “Progress in Immunology,” Academic Press, Japan (1984).

    Google Scholar 

  38. J. W. Hadden and A. Giner-Sorolla, Isoprinosine and NPT 15392: Modulators of lymphocyte and macrophage development and function, in: “Augmenting Agents in Cancer Therapy: Current Status and Future Perspectives,” M. Chirigos and E. Hersh, eds., Raven Press, New York (1980).

    Google Scholar 

  39. J. W. Hadden and A. Giner-Sorolla, Isoprinosine and NPT 15392:Modulators of lymphocyte and macrophage development and function, Prog. Cancer Res. Ther. 16:492 (1981).

    Google Scholar 

  40. J. W. Hadden, A. Giner-Sorolla, E. M. Hadden, S. Ikehara, R. Pahwa, R. Coffey, A. M. Castellazi, C. Jones, K. Maxwell and L. Simon, NPT 16416: A levamisole-like purine with immunomodulatory effects, Int. J. Immunopharmacol. Abst. 4:287 (1982).

    Article  Google Scholar 

  41. J. W. Hadden, E. M. Hadden and R. G. Coffey, Isoprinosine augmentation of phytohemagglutinin induced lymphocyte proliferation, Infect. Immun. 13:382 (1976).

    PubMed  CAS  Google Scholar 

  42. J. W. Hadden, E. M. Hadden, T. Spira, R. Sedlineri, L. Simon and A.Giner-Sorolla, Effects of NPT 15392 in vitro on human leukocyte functions, Int. J. Immunopharmacol. 4:225 (1982).

    Article  PubMed  Google Scholar 

  43. J. W. Hadden, C. Lopez, R. J. O’Reilly and E. M. Hadden, Levamisole and inosiplex: Antiviral agents with immunopotentiating action, Third Conference on Antiviral Substances, Ann. N. Y. Acad. Sci. 284:139 (1977).

    Article  PubMed  CAS  Google Scholar 

  44. P. Hersey, C. Bindon, M. Bradley and E. Hasic, Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in pokeweed mitogen stimulated cultures of B and T cells, Int. J. Immunopharmacol. 6:315 (1984).

    Article  PubMed  CAS  Google Scholar 

  45. S. Ikehara, J. W. Hadden, R. A. Good and R. Pahwa, In vitro effects of two immunopotentiators, isoprinosine and NPT 15392, on murine T cells differentiation and function, Thymus 3:90 (1981).

    Google Scholar 

  46. G. Italia and E. Rizza, Studio clinico sull’ impiego del metisoprinolo nell’ herpes genitalis, Quad. Clin. Ostetrica Ginecologia 37:129 (1982).

    Google Scholar 

  47. C. E. Jones, P. R. Dyken, P. R. Hutteniocher, J. T. Jabbour and K. W. Maxwell, Inosiplex therapy in subacute sclerosing panencephalitis: A multicentre non-randomised study in 98, Lancet 1:1034 (1982).

    Article  PubMed  CAS  Google Scholar 

  48. F. G. Lento, S. Tandurella, C. Baretti, G. Cannata and R. Salerno, Pazienti affetti da herpes zoster trattati con metisoprinolo, G. Ital. Pat. 28:9 (1983).

    Google Scholar 

  49. F. Loiacono, D. Agnello, R. Malizia and M. Balsamo. Il metisoprinolo nel trattamento di alcune affezioni delle vie respiratorie del bambino, Aggior. Pediat. 33:85 (1982).

    Google Scholar 

  50. S. Longley, R. L. Dunning and R. H. Waldman, Effect of isoprinosine against challenge with A(H3N2)/Hong Kong influence virus in volunteers, Antimicrob. Agents Chemother. 3:506 (1973).

    PubMed  CAS  Google Scholar 

  51. V. J. Merluzzi, M. M. Walker, N. Williams, B. Susskind, J. W. Hadden and R. Faanes, Immunoenhancing activity of NPT 15392: A potential immune response modifier, Int. J. Immunopharmacol. 4:219 (1982).

    Article  PubMed  CAS  Google Scholar 

  52. A. Miglietta, M. T. Ventura, F. Dammacco and L. Bonomo, Effetto del metisoprinolo sulla fagocitosi dei monociti e dei granulociti neutrofili in vitro, EOS 2:13 (1981).

    Google Scholar 

  53. G. Migneco, C. LaCascia, S. Mansueto and S. Tripi, Analisi e valutazione delle modificazioni del quadro clinico di epatiti croniche in corso di trattamento con metisoprinolo, Riv. Parassitologia 43:331 (1981).

    Google Scholar 

  54. A. Morin, C. Griscelli and F. Daguillard, Effets de l’ isoprinosine sur l’ activation des lymphocytes humains in vitro, Ann. Immunol. 130:541 (1979).

    Google Scholar 

  55. A. Morin, J. L. Touraine, G. Renoux and J. W. Hadden, Isoprinosine as an immunomodulating agent, in: “International Symposium on New Trends in Human Cancer, Immunology and Cancer Immunotherapy,” B. Serrou and C. Rosenfeld, eds., Doin Editeur, Paris (1980).

    Google Scholar 

  56. H. Ohnishi, H. Kosuzume, I. Hitoshi, O. Masatsugu, Y. Morita, H. Mochizuki and Y. Zusuki, Mechanism of host defense suppression induced by viral infection: Mode of action of inosiplex as an antiviral agent, Infec. Immun. 243:38 (1982).

    Google Scholar 

  57. H. Ohnishi, H. Kosuzume, H. Inaba, M. Okura, S. Shimada, H. Tajima and Y. Suzuki, The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections, Int. J. Immunopharmacol. 5:181 (1983).

    Article  PubMed  CAS  Google Scholar 

  58. D. M. Pachuta, Y. Togo, R. B. Hornick, A. R. Schwartz and S. Tominaga,Evaluation of isoprinosine in experimental human rhinovirus infection, Antimicrob. Agents Chemother. 5:403 (1974).

    PubMed  CAS  Google Scholar 

  59. A. Paffetti, D. Curti, V. Renda, A. Nurzia and S. Carlizzi, II metisoprinolo nella epatite acuta virale di tipo B, Riv. Sci. Med. Farmacol. 5:361 (1983).

    Google Scholar 

  60. E. Pasqui, A. Alzeni, G. Verrocchi, G. Daga and A. Carta, Terapia con metisoprinolo di 50 casi di epatite virale acuta, Riv. Pat. Clin. 35:735 (1980).

    Google Scholar 

  61. A. Polloni, M. Carrai, A. Capria and G. Corsini, Trattamento delle epatiti croniche HB Ag positive con metisoprinolo: Prime esperienze, Riv. Gastroent. 33:41 (1981).

    Google Scholar 

  62. A. Pompidou, In vitro effects of methisoprinol on human peripheral blood lymphocytes, EOS 4:112 (1984).

    CAS  Google Scholar 

  63. G. Precchia, M. Del Vecchio, G. Morelli, P. Tarallo, C. Ciccarello, A. Precchia and P. Amoroso, Il metisoprinolo nella terapia delle malattie viral: dati preliminari sul trattamento di un gruppo di malattie, Chemioter. Antimicrobican. 4:64 (1981).

    Google Scholar 

  64. G. Rancurel and A. Buge, Bull. et Mem. Soc. Med. Paris IX:49 (1981).

    Google Scholar 

  65. G. Rancurel, B. Lesourd, A. Pompidou, D. Denvil, C. Pontes, R. Moulias and A. Buge, Immunological status in necrotic acute encephalitis (NAW), L’infection herpetique humaine et ses traitments, Facultè de Medicine de Brest, Proceedings (1981).

    Google Scholar 

  66. G. Renoux, M. Renoux and D. Degenne, Suppressor cell activity after isoprinosine treatment of lymphocytes from normal mice, Int. J. Immunopharmacol. 1:239 (1979).

    Article  PubMed  CAS  Google Scholar 

  67. G. Renoux, M. Renoux, J. M. Guillaumin and C. Gouzien, Differentiation and regulation of lymphocyte populations -evidence for immunopoten-tiation induced T cell recruitment, Int. J. Immunopharmacol. 1:415 (1979).

    CAS  Google Scholar 

  68. G. Santangelo, S. Lombardo, S. Randazzo, N. Maccarone and M. Amato, Il Virtixan nelle infezioni virali dell’ infanzia: Prospettive terapeutiche nelle infezioni virali ricorrenti dell’ eta del lattante, Aggior. Pediatr. 32:1 (1981).

    Google Scholar 

  69. A. J. Sato, T. S. Hall and S. E. Reed, Trial of the antiviral action of isoprinosine against rhinovirus infection of volunteers, Antimicrob. Agents Chemother. 3:332 (1973).

    Google Scholar 

  70. I. Signorelli, G. Garbarino and S. Tampucci, Studio clinico del metisoprinolo in pazienti affette da condiloma acuminato, G. Ital. Ostet. Ginecol. 4:11 (1982).

    Google Scholar 

  71. L. N. Simon and A. J. Glasky, Isoprinosine: an overview, Cancer Treatment Reports 62:1963 (1978).

    PubMed  CAS  Google Scholar 

  72. L. N. Simon, F. K. Hoehler, T. Ginsberg and J. W. Hadden, NPT 15392:A new chemically defined biological response modifier, in: “Immune Modulation Agents and Their Actions,” E. Fenichel and M. A. Chirigos, eds., Marcel Dekker, Inc., New York, N.Y. (1984).

    Google Scholar 

  73. A. Sinardi, L. Santamaria, C. Practico, L. Siracusano and A. Martino, Su due casi di meningo-encefalite virale trattati con metisoprinolo, Clin. Europa. 22:396 (1983).

    Google Scholar 

  74. S. Spadafora, Il metisoprinolo in alcune virosi cutanee; nostre prime esperienze, Esp. Med. Chir. 1:83 (1981).

    Google Scholar 

  75. S. Specter and J. W. Hadden, Thymomimetic drugs, in: “Immunomodulation,” J. W. Hadden and F. Spreafico, eds., Springer Verlag, in press (1985).

    Google Scholar 

  76. J-L. Touraine, J. W. Hadden and F. Touraine, Isoprinosine-induced T cell differentiation and T cell suppressor activity in humans, in: “Current Chemotherapy and Infectious Disease,” J. D. Nelson and C. Grassi, eds., A.S.M., Washington, D.C. (1980).

    Google Scholar 

  77. J. L. Touraine, B. Serrou, J. W. Hadden, A. Morin and F. Touraine, Modulation of suppressor T cell activity by isoprinosine, in: “International Symposium on New Trends in Human Immunology and Cancer Immunotherapy,” G. Serrou and C. Rosenfeld, eds., Doin, Paris (1980).

    Google Scholar 

  78. S. Tripi, G. Migneco and C. LaCascia, Comportamento dell’ antigene di superficile del virus dell’ epatite B(HB Ag) e del suo anticorpo (HB Ab) in pazienti con epatite acuta trittati con metisoprinolo, Riv. Parassit. 42:345 (1981).

    Google Scholar 

  79. K. Y. Tsang, H. H. Fudenberg, G. M. P. Golbriath, R. P. Donnelly, L. R. Bishop and W. R. Koopenen, Partial restoration of interleukin 2 production and tac (putative interleukin 2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment, J. Clin. Invest. 5:1538 (1985).

    Article  Google Scholar 

  80. A. Vellucci, G. Galanti and A. Delongis, Virus epatite acuta trattata con metisoprinolo. Nostre osservazioni preliminari in 22 casi, G. Mal. Infett. 34:611 (1982).

    Google Scholar 

  81. G. Villa, C. Caltagirone and G. Macchi, Unusual clinical course in a case of Creutzfeldt-Jakob disease, Ital. J. Neurol. Sci. 2:155 (1982).

    Article  Google Scholar 

  82. R. H. Waldman and R. Ganguly, Therapeutic efficacy of inosiplex (isoprinosine) in rhinovirus infection, Ann. N. Y. Acad. Sci. 284:153 (1977).

    Article  PubMed  CAS  Google Scholar 

  83. J. Wybran, A. Govaerts and J. Appleboom, Inosiplex, a stimulating agent for normal human T cells and human leukocytes, J. Immunol. 121:1181 (1978).

    Google Scholar 

  84. J. Wybran, B. Serrou, D. Belpomme, J. Boneterre, A. Desplaces, R.Favre, T. Ginsberg, J. M. Lang, G. Mayer, D. T. McKenzie, M. Miksche, D. C. Petit, G. Renoux, C. Rosenfeld, M. Schneider, L. N. Simon and L. Toujas, Immnnomodulating of T cell and NK function by NPT 15392 in cancer patients, in: “Current Concepts in Human Immunology and Cancer Immunomodulation,” B. Serrou, G. Rosenfeld, J. C. Daniels and J. P. Saunders, eds., Elsevier Biomedical, Netherlands (1982).

    Google Scholar 

  85. G. F. Zagni and C. Cannarozzo, Studio clinico sui metisoprinolo per uso topico in alcune virosi cutanee, Clin. Europea. 21:585 (1982).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Malattie Infettive, Policlinico Umberto I, Rome, Italy

    Claudio DeSimone

  2. Program of Immunopharmacology, University of South Florida College of Medicine, Tampa, Florida, USA

    John W. Hadden

Authors
  1. Claudio DeSimone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. Hadden
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Pharmacology and Therapeutics and Internal Medicine, University of South Florida, College of Medicine, 12901 N. 30th Street, Box 9, Tampa, Florida, USA

    Andor Szentivanyi M.D. (University Distinguished Professor) (University Distinguished Professor)

  2. Department of Medical Microbiology and Immunology, University of South Florida, College of Medicine, 12901 N. 30th Street, Box 10, Tampa, Florida, USA

    Herman Friedman Ph.D. (Professor and Chairman) (Professor and Chairman)

  3. Department of Medical Microbiology, Faculty of Medicine, Rhein.-Westfälische Technische Hochschule Aachen, 5100, Aachen, Federal Republic of Germany

    Günther Gillissen M.D., Ph.D. (Professor and Chairman) (Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Plenum Press, New York

About this chapter

Cite this chapter

DeSimone, C., Hadden, J.W. (1987). Prohost Modulation of Immunity by Isoprinosine and NPT 15392. In: Szentivanyi, A., Friedman, H., Gillissen, G. (eds) Antibiosis and Host Immunity. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1901-6_32

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1901-6_32

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9058-2

  • Online ISBN: 978-1-4613-1901-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation